| PRISM Stock Indexes | Current Value | % Change (Daily) | % Change (Inception) | Most Active | Top % Gainers | Top % Losers |
|---|---|---|---|---|---|---|
| Cannabis | $61.30 | 4.1% | -38.7% | TLRY 24,936 | TLRY 7.5% | HITI -0.704% |
| EV | $60.00 | 4% | -40.0% | GOEV 13,969 | RIDE 10.989% | DCRD 0% |
| Gene Therapy | $58.10 | 4% | -41.9% | BLUE 8,320 | VYGR 15.69% | AGTC -3.91% |
| MedDevices | $168.90 | 2.9% | 68.9% | ATRS 5,230 | STIM 21.849% | ADMP -11.606% |
| MedDiagnostics | $88.20 | 3% | -11.8% | TTOO 43,728 | QTRX 29.156% | ANIX -11.509% |
| Solar | $101.60 | 3.3% | 1.6% | HYSR 8,723 | ISUN 15.196% | NOVA -0.954% |
| Uranium | $88.90 | 6.1% | -11.1% | UEC 9,703 | UROY 8.889% | PALAF 1.585% |
| Vaccines & Cell Therapy | $182.50 | 1.7% | 82.5% | SIGA 9,798 | ATHX 14.789% | IBIO -32.279% |
| Web 3.0 | $44.00 | 5.1% | -56.0% | MARA 19,880 | MARA 10.942% | FTFT -1.626% |
FedEx announced earnings per share of $3.44 on revenue of $23.2B. Analysts polled by Investing.com anticipated EPS of $2.80 on revenue of $23.78B. FedEx shares…
[Read More]
The modern investor needs trusted, relevant information, delivered quickly and concisely. CEO3in60 provides a platform for management to succinctly share their company’s value proposition in their own words. We take the CEOs of the most dynamic up and coming companies and put them in front of the camera to provide you with the top three reasons why you should be paying attention to their business, all in less than sixty seconds.
Asensus Surgical (NYSE American: ASXC) is leading the digital surgical market with Performance-Guided Surgery™, which enhances the work of surgeons using state-of-the-art robotics, augmented intelligence and machine learning. Shameze Rampertab, Chief Financial Officer at Asensus, outlines three value drivers for investors that will have the market paying attention in the coming months.
Soligenix (NASDAQ: SNGX) is developing and commercializing products to treat rare diseases in oncology and dermatology where there is an unmet medical need. Chris Schaber, President and CEO of Soligenix, Inc. spends one minute outlining three value drivers that will have investors
Read more about Soligenix, Inc.
Lexaria Bioscience (Nasdaq: LEXX) (Nasdaq: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, DehydraTECH-CBD, offers an alternative to traditional cannabidiol (CBD) dosing methods, enabling improved and more rapid absorption of drugs into the bloodstream and brain.
There is currently only one FDA approved CBD drug available on the market, used to treat pediatric epilepsy. Lexaria is positioned to potentially deliver the second-ever FDA approved CBD therapeutic, which has the potential to be life-changing for those living with hypertension.
Hypertension is a serious public health issue. Over 116 million Americans, and more than a billion adults worldwide, are living with high blood pressure, a major cause of premature death. However, as hypertension diagnosis numbers continue to climb, there has been a marked slowing of research and development for novel hypertension drugs.
We spoke with Professor Philip Ainslie, PhD, Lead Investigator in Lexaria’s human hypertension studies, to find out more about how Lexaria is working to develop a best-in-class delivery method for hypertension drugs.
